arrow
V

Virginia García-Pineda

fondazione irccs san gerardo dei tintori
H指数:7
被引数:201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PROMISE-EC Study: prognostic role of molecular classification and sentinel lymph node status in early-stage endometrial cancer

PROMISE-EC研究:分子分类和哨兵淋巴结状态在早期子宫内膜癌中的预后作用

2026-09-011
PRE
A Multicenter Retrospective Study Comparing One Step Nucleid Amplification (OSNA) and Conventional Ultrastaging for Sentinel Lymph Node Assessment in Early-Stage Endometrial Cancer

一项多中心回顾性研究,比较单步核糖核酸扩增(OSNA)和常规超分期方法在早期子宫内膜癌前哨淋巴结评估中的应用。

2026-04-030
PRE
The MULTISENT Study: A Multicenter Study on the Detection Rate of Sentinel Lymph Node Mapping in Endometrial Cancer Across Spain

MULTISENT研究:一项关于子宫内膜癌中前哨淋巴结显像检出率的多中心研究(西班牙)

2025-07-230
PRE
SLYMEC II study: Overall survival analysis of the impact of LVSI in apparent early stage endometrioid endometrial cancer
EJSO
IF2.9
2025-03-010
PRE
The Prognostic Impact Of Molecular Classification In Women With Uterine Confined Endometrial Cancer In The Sentinel Node Era. A Large Multicentric International Study.

分子分类在哨兵淋巴结时代对局限于子宫的子宫内膜癌女性的预后影响。一项大规模多中心国际研究。

2025-02-010
PRE
Long-Term Prognostic Impact Of LVSI In Apparent Early-Stage Endometrioid Endometrial Cancer: The SLYM-EC II Retrospective International Collaborative Study.

LVSI在表观早期子宫内膜样子宫内膜癌中的长期预后影响:SLYM-EC II回顾性国际协作研究。

2025-02-010
PRE
The impact of Substantial LYMphovascular space invasion on sentinel lymph nodes status and recurrence in Endometrial Cancer patients: SLYM-EC a multicenter retrospective study
EJSO
IF2.9
2024-12-012
PRE
Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application
2024-09-200
OAAI
Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer
2023-08-266
OAAI
ASO Visual Abstract: Accuracy and Survival Outcomes After National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer
2023-08-211
PRE